{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:46:45Z","timestamp":1791254805141,"version":"4.1.0"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Geriatr Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this clinical narrative review was to summarise the existing knowledge on the use of anticoagulants and potential adverse events in older people at risk of falls with a history of atrial fibrillation or venous thromboembolism. The review also offers practical steps prescribers can take when (de-)prescribing anticoagulants to maximise safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Literature searches were conducted using PubMed, Embase and Scopus. Additional articles were identified by searching reference lists.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Anticoagulants are often underused in older people due to concerns about the risk of falls and intracranial haemorrhage. However, evidence suggests that the absolute risk is low and outweighed by the reduction in stroke risk. DOACs are now recommended first line for most patients due to their favourable safety profile. Off-label dose reduction of DOACs is not recommended due to reduced efficacy with limited reduction in bleeding risk. Medication review and falls prevention strategies should be implemented before prescribing anticoagulation. Deprescribing should be considered in severe frailty, limited life expectancy and increased bleeding risk (e.g., cerebral microbleeds).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>When considering whether to (de-)prescribe anticoagulants, it is important to consider the risks associated with stopping therapy in addition to potential adverse events. Shared decision-making with the patient and their carers is crucial as patient and prescriber views often differ.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s41999-023-00811-z","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T08:02:31Z","timestamp":1688198551000},"page":"683-696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Anticoagulant use in older persons at risk for falls: therapeutic dilemmas\u2014a clinical review"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9222-3185","authenticated-orcid":false,"given":"Anneka","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4794-612X","authenticated-orcid":false,"given":"Yasmin","family":"Elmasry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-5602","authenticated-orcid":false,"given":"Eveline","family":"van Poelgeest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2619-5032","authenticated-orcid":false,"given":"Tomas J.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"key":"811_CR1","unstructured":"National Institute for Health and Care Excellence (NICE) (2013) CG161: Falls in older people: assessing risk and prevention. Available from: https:\/\/www.nice.org.uk\/guidance\/cg161. Accessed 12 Nov 2022"},{"issue":"5","key":"811_CR2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/EDE.0b013e3181e89905","volume":"21","author":"S Deandrea","year":"2010","unstructured":"Deandrea S, Lucenteforte E, Bravi F, Foschi R, La Vecchia C, Negri E (2010) Risk factors for falls in community-dwelling older people: a systematic review and meta-analysis. Epidemiology 21(5):658\u2013668","journal-title":"Epidemiology"},{"issue":"Supp 1","key":"811_CR3","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1136\/injuryprev-2019-043286","volume":"26","author":"SL James","year":"2020","unstructured":"James SL, Lucchesi LR, Bisignano C, Castle CD, Dingels ZV, Fox JT et al (2020) The global burden of falls: global, regional and national estimates of morbidity and mortality from the Global Burden of Disease Study 2017. Inj Prev 26(Supp 1):i3\u2013i11","journal-title":"Inj Prev"},{"issue":"1","key":"811_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11556-013-0134-8","volume":"11","author":"M Terroso","year":"2013","unstructured":"Terroso M, Rosa N, Torres Marques A, Simoes R (2013) Physical consequences of falls in the elderly: a literature review from 1995 to 2010. Eur Rev Aging Phys Act 11(1):51\u201359","journal-title":"Eur Rev Aging Phys Act"},{"issue":"8","key":"811_CR5","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","volume":"27","author":"J Heeringa","year":"2006","unstructured":"Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH et al (2006) Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27(8):949\u2013953","journal-title":"Eur Heart J"},{"issue":"9","key":"811_CR6","doi-asserted-by":"publisher","first-page":"afac205","DOI":"10.1093\/ageing\/afac205","volume":"51","author":"M Montero-Odasso","year":"2022","unstructured":"Montero-Odasso M, van der Velde N, Martin FC, Petrovic M, Tan MP, Ryg J et al (2022) World guidelines for falls prevention and management for older adults: a global initiative. Age Ageing 51(9):afac205","journal-title":"Age Ageing"},{"issue":"4","key":"811_CR7","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/ageing\/afv017","volume":"44","author":"S Jansen","year":"2015","unstructured":"Jansen S, Frewen J, Finucane C, de Rooij SE, van der Velde N, Kenny RA (2015) AF is associated with self-reported syncope and falls in a general population cohort. Age Ageing 44(4):598\u2013603","journal-title":"Age Ageing"},{"issue":"3","key":"811_CR8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/ageing\/afaa265","volume":"50","author":"C Wilkinson","year":"2021","unstructured":"Wilkinson C, Clegg A, Todd O, Rockwood K, Yadegarfar ME, Gale CP et al (2021) Atrial fibrillation and oral anticoagulation in older people with frailty: a nationwide primary care electronic health records cohort study. Age Ageing 50(3):772\u2013779","journal-title":"Age Ageing"},{"issue":"2","key":"811_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1161\/01.STR.32.2.392","volume":"32","author":"M Lamassa","year":"2001","unstructured":"Lamassa M, Di Carlo A, Pracucci G, Basile AM, Trefoloni G, Vanni P et al (2001) Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 32(2):392\u2013398","journal-title":"Stroke"},{"issue":"5","key":"811_CR10","first-page":"1279","volume":"8","author":"AN Ali","year":"2016","unstructured":"Ali AN, Abdelhafiz A (2016) Clinical and economic implications of AF related stroke. J Atr Fibrillation 8(5):1279","journal-title":"J Atr Fibrillation"},{"issue":"9586","key":"811_CR11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","volume":"370","author":"J Mant","year":"2007","unstructured":"Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY et al (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370(9586):493\u2013503","journal-title":"Lancet"},{"issue":"7","key":"811_CR12","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","volume":"123","author":"IM Ogilvie","year":"2010","unstructured":"Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY (2010) Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 123(7):638\u2013645","journal-title":"Am J Med"},{"issue":"9","key":"811_CR13","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/j.1532-5415.1997.tb05967.x","volume":"45","author":"J Monette","year":"1997","unstructured":"Monette J, Gurwitz JH, Rochon PA, Avorn J (1997) Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc 45(9):1060\u20131065","journal-title":"J Am Geriatr Soc"},{"key":"811_CR14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1747-4949.2010.00539.x","volume":"6","author":"D Pugh","year":"2011","unstructured":"Pugh D, Mead GE, Pugh J (2011) Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Int J Stroke 6:42","journal-title":"Int J Stroke"},{"issue":"3","key":"811_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0167-4943(01)00184-4","volume":"33","author":"S Vasishta","year":"2001","unstructured":"Vasishta S, Toor F, Johansen A, Hasan M (2001) Stroke prevention in atrial fibrillation: physicians\u2019 attitudes to anticoagulation in older people. Arch Gerontol Geriatr 33(3):219\u2013226","journal-title":"Arch Gerontol Geriatr"},{"key":"811_CR16","unstructured":"National Institute for Health and Care Excellence (NICE) (2009) CG76: Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. Available from: https:\/\/www.nice.org.uk\/guidance\/cg76. Accessed 12 Nov 2022"},{"issue":"1","key":"811_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12875-016-0574-0","volume":"18","author":"G Mas Dalmau","year":"2017","unstructured":"Mas Dalmau G, Sant Arderiu E, Enfedaque Montes MB, Sol\u00e0 I, Peque\u00f1o Saco S, Alonso CP (2017) Patients\u2019 and physicians\u2019 perceptions and attitudes about oral anticoagulation and atrial fibrillation: a qualitative systematic review. BMC Fam Pract 18(1):3","journal-title":"BMC Fam Pract"},{"issue":"4","key":"811_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/1474515118812252","volume":"18","author":"SD Pokorney","year":"2019","unstructured":"Pokorney SD, Bloom D, Granger CB, Thomas KL, Al-Khatib SM, Roettig ML et al (2019) Exploring patient\u2013provider decision-making for use of anticoagulation for stroke prevention in atrial fibrillation: results of the INFORM-AF study. Eur J Cardiovasc Nurs 18(4):280\u2013288","journal-title":"Eur J Cardiovasc Nurs"},{"issue":"3","key":"811_CR19","first-page":"465","volume":"111","author":"S LaHaye","year":"2014","unstructured":"LaHaye S, Regpala S, Lacombe S, Sharma M, Gibbens S, Ball D et al (2014) Evaluation of patients\u2019 attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 111(3):465\u2013473","journal-title":"Thromb Haemost"},{"issue":"6","key":"811_CR20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1160\/TH16-10-0787","volume":"117","author":"PS Loewen","year":"2017","unstructured":"Loewen PS, Ji AT, Kapanen A, McClean A (2017) Patient values and preferences for antithrombotic therapy in atrial fibrillation. Thromb Haemost 117(6):1007\u20131022","journal-title":"Thromb Haemost"},{"issue":"5","key":"811_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C et al (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42(5):373\u2013498","journal-title":"Eur Heart J"},{"issue":"9","key":"811_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065066","volume":"12","author":"K Williams","year":"2022","unstructured":"Williams K, Modi RN, Dymond A, Hoare S, Powell A, Burt J et al (2022) Cluster randomised controlled trial of screening for atrial fibrillation in people aged 70 years and over to reduce stroke: protocol for the pilot study for the SAFER trial. BMJ Open 12(9):e065066","journal-title":"BMJ Open"},{"key":"811_CR23","unstructured":"National Institute for Health and Care Excellence (NICE) (2021) NG196: Atrial fibrillation: diagnosis and management. Available from: https:\/\/www.nice.org.uk\/guidance\/ng196. Accessed 12 Nov 2022"},{"key":"811_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02067-5","author":"A Mitchell","year":"2021","unstructured":"Mitchell A, Snowball J, Welsh TJ, Watson MC, McGrogan A (2021) Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study. BMC Med. https:\/\/doi.org\/10.1186\/s12916-021-02067-5","journal-title":"BMC Med"},{"issue":"3","key":"811_CR25","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/bcp.14464","volume":"87","author":"P Mongkhon","year":"2021","unstructured":"Mongkhon P, Alwafi H, Fanning L, Lau WCY, Wei L, Kongkaew C et al (2021) Patterns and factors influencing oral anticoagulant prescription in people with atrial fibrillation and dementia: results from UK primary care. Br J Clin Pharmacol 87(3):1056\u20131068","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"811_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ahj.2014.07.002","volume":"168","author":"EC O'Brien","year":"2014","unstructured":"O\u2019Brien EC, Simon DN, Allen LA, Singer DE, Fonarow GC, Kowey PR et al (2014) Reasons for warfarin discontinuation in the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF). Am Heart J 168(4):487\u2013494","journal-title":"Am Heart J"},{"issue":"7","key":"811_CR27","first-page":"CD012221","volume":"7","author":"S Hopewell","year":"2018","unstructured":"Hopewell S, Adedire O, Copsey BJ, Boniface GJ, Sherrington C, Clemson L et al (2018) Multifactorial and multiple component interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 7(7):CD012221","journal-title":"Cochrane Database Syst Rev"},{"key":"811_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2016.12.021","volume":"38","author":"E Reeve","year":"2017","unstructured":"Reeve E, Thompson W, Farrell B (2017) Deprescribing: a narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. Eur J Intern Med 38:3\u201311","journal-title":"Eur J Intern Med"},{"key":"811_CR29","unstructured":"National Institute for Health and Care Excellence (NICE) (2018) NG89: venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. Available from: https:\/\/www.nice.org.uk\/guidance\/ng89. Accessed 30 Nov 2022"},{"issue":"7","key":"811_CR30","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2021","unstructured":"Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J et al (2021) 2021 ESC\/EACTS guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 43(7):561\u2013632","journal-title":"Eur Heart J"},{"issue":"7","key":"811_CR31","doi-asserted-by":"publisher","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","volume":"131","author":"RG Hart","year":"1999","unstructured":"Hart RG, Benavente O, McBride R, Pearce LA (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131(7):492\u2013501","journal-title":"Ann Intern Med"},{"issue":"46","key":"811_CR32","first-page":"3258","volume":"36","author":"EC O'Brien","year":"2015","unstructured":"O\u2019Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE et al (2015) The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 36(46):3258\u20133264","journal-title":"Eur Heart J"},{"issue":"11","key":"811_CR33","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119\u20132126","journal-title":"J Thromb Haemost"},{"issue":"5","key":"811_CR34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138(5):1093\u20131100","journal-title":"Chest"},{"issue":"6","key":"811_CR35","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.amjmed.2015.10.001","volume":"129","author":"K Senoo","year":"2016","unstructured":"Senoo K, Proietti M, Lane DA, Lip GY (2016) Evaluation of the HAS-BLED, ATRIA, and ORBIT bleeding risk scores in patients with atrial fibrillation taking warfarin. Am J Med 129(6):600\u2013607","journal-title":"Am J Med"},{"issue":"10","key":"811_CR36","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1253\/circj.CJ-16-0471","volume":"80","author":"MA Esteve-Pastor","year":"2016","unstructured":"Esteve-Pastor MA, Garc\u00eda-Fern\u00e1ndez A, Mac\u00edas M, Sogorb F, Vald\u00e9s M, Rold\u00e1n V et al (2016) Is the ORBIT bleeding risk score superior to the HAS-BLED score in anticoagulated atrial fibrillation patients? Circ J 80(10):2102\u20132108","journal-title":"Circ J"},{"issue":"65","key":"811_CR37","doi-asserted-by":"publisher","first-page":"109703","DOI":"10.18632\/oncotarget.19858","volume":"8","author":"C Wang","year":"2017","unstructured":"Wang C, Yu Y, Zhu W, Yu J, Lip GYH, Hong K (2017) Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis. Oncotarget 8(65):109703\u2013109711","journal-title":"Oncotarget"},{"key":"811_CR38","unstructured":"National Institute for Health and Care Excellence (NICE) (2020) Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. Available from: https:\/\/www.nice.org.uk\/guidance\/ng158\/resources\/venous-thromboembolic-diseases-diagnosis-management-and-thrombophilia-testing-pdf-66141847001797. Accessed 12 Nov 2022"},{"issue":"4","key":"811_CR39","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP et al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41(4):543\u2013603","journal-title":"Eur Heart J"},{"issue":"13","key":"811_CR40","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1161\/CIRCULATIONAHA.109.853119","volume":"121","author":"JW Eikelboom","year":"2010","unstructured":"Eikelboom JW, Weitz JI (2010) New anticoagulants. Circulation 121(13):1523\u20131532","journal-title":"Circulation"},{"issue":"21","key":"811_CR41","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","volume":"123","author":"JW Eikelboom","year":"2011","unstructured":"Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J et al (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. Circulation 123(21):2363\u20132372","journal-title":"Circulation"},{"issue":"28","key":"811_CR42","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","volume":"35","author":"S Halvorsen","year":"2014","unstructured":"Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D et al (2014) Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 35(28):1864\u20131872","journal-title":"Eur Heart J"},{"key":"811_CR43","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","volume":"130","author":"JL Halperin","year":"2014","unstructured":"Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR et al (2014) Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with non-valvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial. Circulation 130:138\u2013146","journal-title":"Circulation"},{"issue":"6","key":"811_CR44","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.amjmed.2018.12.036","volume":"132","author":"G Patti","year":"2019","unstructured":"Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G et al (2019) Net clinical benefit of non-vitamin K antagonist vs vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation. Am J Med 132(6):749\u2013757","journal-title":"Am J Med"},{"issue":"4","key":"811_CR45","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/jcm8040554","volume":"8","author":"A Mitchell","year":"2019","unstructured":"Mitchell A, Watson MC, Welsh T, McGrogan A (2019) Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists for people aged 75 years and over with atrial fibrillation: a systematic review and meta-analyses of observational studies. J Clin Med 8(4):554","journal-title":"J Clin Med"},{"issue":"1","key":"811_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/ageing\/afx103","volume":"47","author":"Y Bai","year":"2018","unstructured":"Bai Y, Guo SD, Deng H, Shantsila A, Fauchier L, Ma CS et al (2018) Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. Age Ageing 47(1):9\u201317","journal-title":"Age Ageing"},{"issue":"9","key":"811_CR47","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799\u2013808","journal-title":"N Engl J Med"},{"issue":"15","key":"811_CR48","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"The Hokusai-VTE Investigators","year":"2013","unstructured":"The Hokusai-VTE Investigators (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406\u20131415","journal-title":"N Engl J Med"},{"issue":"26","key":"811_CR49","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"The EINSTEIN Investigators","year":"2010","unstructured":"The EINSTEIN Investigators (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499\u20132510","journal-title":"N Engl J Med"},{"issue":"14","key":"811_CR50","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"The EINSTEIN-PE Investigators","year":"2012","unstructured":"The EINSTEIN-PE Investigators (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287\u20131297","journal-title":"N Engl J Med"},{"issue":"24","key":"811_CR51","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342\u20132352","journal-title":"N Engl J Med"},{"issue":"7","key":"811_CR52","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","volume":"129","author":"S Schulman","year":"2014","unstructured":"Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P et al (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129(7):764\u2013772","journal-title":"Circulation"},{"issue":"3","key":"811_CR53","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/jth.12485","volume":"12","author":"T van der Hulle","year":"2014","unstructured":"van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV (2014) Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 12(3):320\u2013328","journal-title":"J Thromb Haemost"},{"issue":"1","key":"811_CR54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1477-9560-12-21","volume":"12","author":"V Geldhof","year":"2014","unstructured":"Geldhof V, Vandenbriele C, Verhamme P, Vanassche T (2014) Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. Thromb J 12(1):21","journal-title":"Thromb J"},{"key":"811_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5058","volume":"359","author":"JA L\u00f3pez-L\u00f3pez","year":"2017","unstructured":"L\u00f3pez-L\u00f3pez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN et al (2017) Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 359:j5058","journal-title":"BMJ"},{"issue":"6","key":"811_CR56","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/ageing\/afu101","volume":"43","author":"C Fox","year":"2014","unstructured":"Fox C, Smith T, Maidment I, Hebding J, Madzima T, Cheater F et al (2014) The importance of detecting and managing comorbidities in people with dementia? Age Ageing 43(6):741\u2013743","journal-title":"Age Ageing"},{"issue":"4","key":"811_CR57","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00002512-200522040-00007","volume":"22","author":"BAJ van Deelen","year":"2005","unstructured":"van Deelen BAJ, van den Bemt PMLA, Egberts TCG, van\u2019t Hoff A, Maas HAAM (2005) Cognitive impairment as determinant for sub-optimal control of oral anticoagulation treatment in elderly patients with atrial fibrillation. Drugs Aging 22(4):353\u201360","journal-title":"Drugs Aging"},{"issue":"3","key":"811_CR58","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3233\/JAD-170575","volume":"61","author":"A Subic","year":"2018","unstructured":"Subic A, Cermakova P, Religa D, Han S, von Euler M, K\u00e5reholt I et al (2018) Treatment of atrial fibrillation in patients with dementia: a cohort study from the Swedish Dementia Registry. J Alzheimers Dis 61(3):1119\u20131128","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"811_CR59","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/jgs.14099","volume":"64","author":"MH Eckman","year":"2016","unstructured":"Eckman MH, Lip GYH, Wise RE, Speer B, Sullivan M, Walker N et al (2016) Using an atrial fibrillation decision support tool for thromboprophylaxis in atrial fibrillation: effect of sex and age. J Am Geriatr Soc 64(5):1054\u20131060","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"811_CR60","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S et al (2011) Apixaban in patients with atrial fibrillation. New Engl J Med 364(9):806\u2013817","journal-title":"New Engl J Med"},{"issue":"1","key":"811_CR61","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/bcpt.13283","volume":"126","author":"M Hellfritzsch","year":"2020","unstructured":"Hellfritzsch M, Adelborg K, Damkier P, Paaske Johnsen S, Hallas J, Potteg\u00e5rd A et al (2020) Effectiveness and safety of direct oral anticoagulants in atrial fibrillation patients switched from vitamin K antagonists: a systematic review and meta-analysis. Basic Clin Pharmacol Toxicol 126(1):21\u201331","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"12","key":"811_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-032488","volume":"9","author":"LPT Joosten","year":"2019","unstructured":"Joosten LPT, van Doorn S, Hoes AW, Nierman MC, Wiersma NM, Koek HL et al (2019) Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial. BMJ Open 9(12):e032488","journal-title":"BMJ Open"},{"issue":"5","key":"811_CR63","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496\u2013520","journal-title":"J Clin Oncol"},{"issue":"7","key":"811_CR64","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C et al (2022) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334\u2013e347","journal-title":"Lancet Oncol"},{"issue":"7","key":"811_CR65","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2017","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al (2017) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615\u2013624","journal-title":"N Engl J Med"},{"issue":"20","key":"811_CR66","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C et al (2018) Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017\u20132023","journal-title":"J Clin Oncol"},{"issue":"2","key":"811_CR67","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane II","year":"2020","unstructured":"McBane RD II, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 18(2):411\u2013421","journal-title":"J Thromb Haemost"},{"issue":"17","key":"811_CR68","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, Mu\u00f1oz A, Huisman MV, Connors JM et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382(17):1599\u20131607","journal-title":"N Engl J Med"},{"issue":"8","key":"811_CR69","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/jth.14478","volume":"17","author":"A Delluc","year":"2019","unstructured":"Delluc A, Wang T-F, Yap E-S, Ay C, Schaefer J, Carrier M et al (2019) Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH. J Thromb Haemost 17(8):1247\u20131252","journal-title":"J Thromb Haemost"},{"key":"811_CR70","unstructured":"Boehringer Ingelheim Limited (2022) Pradaxa 150 mg hard capsules SmPC. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/4703\/smpc#gref. Accessed 2 Oct 2022"},{"key":"811_CR71","unstructured":"Bayer plc (2022) Xarelto 20mg film-coated tablets SmPC. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/2793\/smpc#gref. Accessed 2 Oct 2022"},{"key":"811_CR72","unstructured":"Bristol-Myers Squibb-Pfizer. Eliquis 5 mg film-coated tablets SmPC. 2022. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/2878\/smpc#gref. Accessed 2 Oct 2022"},{"key":"811_CR73","unstructured":"Daiichi Sankyo UK Limited (2022) Lixiana 60mg Film-Coated Tablets SmPC. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/6905\/smpc#gref. Accessed 2 Oct 2022"},{"issue":"6","key":"811_CR74","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014108","volume":"9","author":"S Sanghai","year":"2020","unstructured":"Sanghai S, Wong C, Wang Z, Clive P, Tran W, Waring M et al (2020) Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study. J Am Heart Assoc 9(6):e014108","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"811_CR75","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.amjmed.2019.01.025","volume":"132","author":"R Arbel","year":"2019","unstructured":"Arbel R, Sergienko R, Hammerman A, Greenberg-Dotan S, Batat E, Avnery O et al (2019) Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation. Am J Med 132(7):847\u2013855","journal-title":"Am J Med"},{"issue":"4","key":"811_CR76","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007633","volume":"7","author":"BA Steinberg","year":"2018","unstructured":"Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J et al (2018) Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (the outcomes registry for better informed treatment of atrial fibrillation II). J Am Heart Assoc 7(4):e007633","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"811_CR77","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1113697","volume":"368","author":"S Schulman","year":"2013","unstructured":"Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D et al (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368(8):709\u2013718","journal-title":"N Engl J Med"},{"issue":"13","key":"811_CR78","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","volume":"376","author":"JI Weitz","year":"2017","unstructured":"Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H et al (2017) Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 376(13):1211\u20131222","journal-title":"N Engl J Med"},{"issue":"8","key":"811_CR79","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","volume":"368","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al (2013) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368(8):699\u2013708","journal-title":"N Engl J Med"},{"issue":"7","key":"811_CR80","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1136\/heartjnl-2018-313617","volume":"105","author":"KL Wang","year":"2019","unstructured":"Wang KL, van Es N, Cameron C, Castellucci LA, Buller HR, Carrier M (2019) Extended treatment of venous thromboembolism: a systematic review and network meta-analysis. Heart 105(7):545\u2013552","journal-title":"Heart"},{"issue":"8","key":"811_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044064","volume":"7","author":"AL Jorgensen","year":"2012","unstructured":"Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR (2012) Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One 7(8):e44064","journal-title":"PLoS One"},{"issue":"24","key":"811_CR82","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMoa1311386","volume":"369","author":"M Pirmohamed","year":"2013","unstructured":"Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T et al (2013) A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 369(24):2294\u20132303","journal-title":"N Engl J Med"},{"issue":"1","key":"811_CR83","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12916-019-1308-7","volume":"17","author":"AL Jorgensen","year":"2019","unstructured":"Jorgensen AL, Prince C, Fitzgerald G, Hanson A, Downing J, Reynolds J et al (2019) Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study. BMC Med 17(1):76","journal-title":"BMC Med"},{"issue":"1","key":"811_CR84","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10557-018-6774-1","volume":"32","author":"AS Tseng","year":"2018","unstructured":"Tseng AS, Patel RD, Quist HE, Kekic A, Maddux JT, Grilli CB et al (2018) Clinical review of the pharmacogenomics of direct oral anticoagulants. Cardiovasc Drugs Ther 32(1):121\u2013126","journal-title":"Cardiovasc Drugs Ther"},{"key":"811_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00480","author":"A Villari","year":"2017","unstructured":"Villari A, Giurdanella G, Bucolo C, Drago F, Salomone S (2017) Apixaban enhances vasodilatation mediated by protease-activated receptor 2 in isolated rat arteries. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2017.00480","journal-title":"Front Pharmacol"},{"issue":"23","key":"811_CR86","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1182\/blood.V126.23.2334.2334","volume":"126","author":"J Mabley","year":"2015","unstructured":"Mabley J, Scutt G, Lang KJ, Patel JP, Arya R (2015) Rivaroxaban-mediated vascular relaxation as a potential cause of headaches and dizziness. Blood 126(23):2334","journal-title":"Blood"},{"issue":"15","key":"811_CR87","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1001\/archinte.159.15.1750","volume":"159","author":"PJ Caraballo","year":"1999","unstructured":"Caraballo PJ, Heit JA, Atkinson EJ, Silverstein MD, O\u2019Fallon WM, Castro MR et al (1999) Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med 159(15):1750\u20131756","journal-title":"Arch Intern Med"},{"issue":"2","key":"811_CR88","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archinte.166.2.241","volume":"166","author":"BF Gage","year":"2006","unstructured":"Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF (2006) Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 166(2):241\u2013246","journal-title":"Arch Intern Med"},{"issue":"3","key":"811_CR89","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ijcard.2006.07.022","volume":"118","author":"L Rejnmark","year":"2007","unstructured":"Rejnmark L, Vestergaard P, Mosekilde L (2007) Fracture risk in users of oral anticoagulants: a nationwide case-control study. Int J Cardiol 118(3):338\u2013344","journal-title":"Int J Cardiol"},{"issue":"6","key":"811_CR90","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00198-014-2662-0","volume":"25","author":"D Misra","year":"2014","unstructured":"Misra D, Zhang Y, Peloquin C, Choi HK, Kiel DP, Neogi T (2014) Incident long-term warfarin use and risk of osteoporotic fractures: propensity-score matched cohort of elders with new onset atrial fibrillation. Osteoporos Int 25(6):1677\u20131684","journal-title":"Osteoporos Int"},{"issue":"5","key":"811_CR91","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/pds.888","volume":"13","author":"D Pilon","year":"2004","unstructured":"Pilon D, Castilloux AM, Dorais M, LeLorier J (2004) Oral anticoagulants and the risk of osteoporotic fractures among elderly. Pharmacoepidemiol Drug Saf 13(5):289\u2013294","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"811_CR92","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s11606-018-4758-2","volume":"34","author":"W Fiordellisi","year":"2019","unstructured":"Fiordellisi W, White K, Schweizer M (2019) A systematic review and meta-analysis of the association between vitamin K antagonist use and fracture. J Gen Intern Med 34(2):304\u2013311","journal-title":"J Gen Intern Med"},{"issue":"1","key":"811_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M19-3671","volume":"173","author":"WCY Lau","year":"2020","unstructured":"Lau WCY, Cheung CL, Man KKC, Chan EW, Sing CW, Lip GYH et al (2020) Association between treatment with apixaban, dabigatran, rivaroxaban, or warfarin and risk for osteoporotic fractures among patients with atrial fibrillation: a population-based cohort study. Ann Intern Med 173(1):1\u20139","journal-title":"Ann Intern Med"},{"issue":"6","key":"811_CR94","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/jnnp-2013-306476","volume":"85","author":"MTC Poon","year":"2014","unstructured":"Poon MTC, Fonville AF, Al-Shahi SR (2014) Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 85(6):660","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"811_CR95","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.amjmed.2005.02.022","volume":"118","author":"BF Gage","year":"2005","unstructured":"Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW (2005) Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 118(6):612\u2013617","journal-title":"Am J Med"},{"key":"811_CR96","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1007\/s00068-022-02016-8","volume":"48","author":"T Vedin","year":"2022","unstructured":"Vedin T, Lundager Forberg J, Anefj\u00e4ll E, Lehtinen R, Faisal M, Edelhamre M (2022) Antiplatelet therapy contributes to a higher risk of traumatic intracranial hemorrhage compared to anticoagulation therapy in ground-level falls: a single-center retrospective study. Eur J Trauma Emerg Surg 48:4909\u20134917","journal-title":"Eur J Trauma Emerg Surg"},{"issue":"5","key":"811_CR97","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1007\/s00068-022-01938-7","volume":"48","author":"C Nederpelt","year":"2022","unstructured":"Nederpelt C, Naar L, Meier K, van Wijck S, Krijnen P, Velmahos G et al (2022) Treatment and outcomes of anticoagulated geriatric trauma patients with traumatic intracranial hemorrhage after falls. Eur J Trauma Emerg Surg 48(5):4297\u20134304","journal-title":"Eur J Trauma Emerg Surg"},{"issue":"10","key":"811_CR98","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/acem.13217","volume":"24","author":"M Ganetsky","year":"2017","unstructured":"Ganetsky M, Lopez G, Coreanu T, Novack V, Horng S, Shapiro NI et al (2017) Risk of intracranial hemorrhage in ground-level fall with antiplatelet or anticoagulant agents. Acad Emerg Med 24(10):1258\u20131266","journal-title":"Acad Emerg Med"},{"issue":"2","key":"811_CR99","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/TA.0000000000002985","volume":"90","author":"SM Fakhry","year":"2021","unstructured":"Fakhry SM, Morse JL, Garland JM, Wilson NY, Shen Y, Wyse RJ et al (2021) Antiplatelet and anticoagulant agents have minimal impact on traumatic brain injury incidence, surgery, and mortality in geriatric ground level falls: a multi-institutional analysis of 33,710 patients. J Trauma Acute Care Surg 90(2):215\u2013223","journal-title":"J Trauma Acute Care Surg"},{"issue":"4","key":"811_CR100","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.amjsurg.2014.05.019","volume":"208","author":"CE Collins","year":"2014","unstructured":"Collins CE, Witkowski ER, Flahive JM, Anderson FA, Santry HP (2014) Effect of preinjury warfarin use on outcomes after head trauma in Medicare beneficiaries. Am J Surg 208(4):544\u2013549","journal-title":"Am J Surg"},{"issue":"1","key":"811_CR101","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s42466-022-00183-y","volume":"4","author":"W Pfeilschifter","year":"2022","unstructured":"Pfeilschifter W, Lindhoff-Last E, Alhashim A, Zydek B, Lindau S, Konstantinides S et al (2022) Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry. Neurol Res Pract 4(1):16","journal-title":"Neurol Res Pract"},{"issue":"12","key":"811_CR102","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139\u20131151","journal-title":"N Engl J Med"},{"issue":"11","key":"811_CR103","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 365(11):981\u2013992","journal-title":"New Engl J Med"},{"issue":"10","key":"811_CR104","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al (2011) Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med 365(10):883\u2013891","journal-title":"N Engl J Med"},{"issue":"22","key":"811_CR105","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093\u20132104","journal-title":"N Engl J Med"},{"issue":"3","key":"811_CR106","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.amjmed.2017.10.036","volume":"131","author":"MP Rao","year":"2018","unstructured":"Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM et al (2018) Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation: insights from the ARISTOTLE trial. Am J Med 131(3):269\u2013275","journal-title":"Am J Med"},{"issue":"11","key":"811_CR107","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jacc.2016.06.034","volume":"68","author":"J Steffel","year":"2016","unstructured":"Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y et al (2016) Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF\u2013TIMI 48 analysis. J Am Coll Cardiol 68(11):1169\u20131178","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"811_CR108","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40264-022-01231-x","volume":"45","author":"T Galvain","year":"2022","unstructured":"Galvain T, Hill R, Donegan S, Lisboa P, Lip GYH, Czanner G (2022) Efficacy and safety of anticoagulants in patients with atrial fibrillation and history of falls or risk of falls: a systematic review and multilevel meta-analysis. Drug Saf 45(11):1349\u20131362","journal-title":"Drug Saf"},{"issue":"3","key":"811_CR109","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s11239-019-01898-7","volume":"48","author":"B Miao","year":"2019","unstructured":"Miao B, Alberts MJ, Bunz TJ, Coleman CI (2019) Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls. J Thromb Thrombolysis 48(3):366\u2013372","journal-title":"J Thromb Thrombolysis"},{"key":"811_CR110","unstructured":"National Institute for Health and Care Excellence (NICE) (2019) CG176: head injury: assessment and early management. Available from: https:\/\/www.nice.org.uk\/guidance\/cg176. Accessed 02 May 2023"},{"key":"811_CR111","unstructured":"National Institute for Health and Care Excellence (NICE) (2022) Head injury: assessment and early management - draft for consultation. Available from: https:\/\/www.nice.org.uk\/guidance\/gid-ng10164\/documents\/draft-guideline. Accessed 02 May 2023"},{"issue":"1","key":"811_CR112","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014324","volume":"7","author":"S Mason","year":"2017","unstructured":"Mason S, Kuczawski M, Teare MD, Stevenson M, Goodacre S, Ramlakhan S et al (2017) AHEAD Study: an observational study of the management of anticoagulated patients who suffer head injury. BMJ Open 7(1):e014324","journal-title":"BMJ Open"},{"issue":"11","key":"811_CR113","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/emermed-2019-209307","volume":"37","author":"G Fuller","year":"2020","unstructured":"Fuller G, Sabir L, Evans R, Bradbury D, Kuczawski M, Mason SM (2020) Risk of significant traumatic brain injury in adults with minor head injury taking direct oral anticoagulants: a cohort study and updated meta-analysis. Emerg Med J 37(11):666\u2013673","journal-title":"Emerg Med J"},{"issue":"4","key":"811_CR114","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-066426","volume":"13","author":"F Tokioka","year":"2023","unstructured":"Tokioka F, Okamoto H, Shiotsu A, Hashimoto T (2023) Frequency and clinical features of radiographic head injury caused by inpatient falls: a single-centre retrospective cohort study. BMJ Open 13(4):e066426","journal-title":"BMJ Open"},{"issue":"1","key":"811_CR115","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/WCO.0000000000000411","volume":"30","author":"D Wilson","year":"2017","unstructured":"Wilson D, Werring D (2017) Antithrombotic therapy in patients with cerebral microbleeds. Curr Opin Neurol 30(1):38\u201347","journal-title":"Curr Opin Neurol"},{"key":"811_CR116","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1212\/WNL.0000000000004704","volume":"89","author":"A Charidimou","year":"2017","unstructured":"Charidimou A, Karayiannis C, Song T-J, Orken DN, Thijs V, Lemmens R et al (2017) Brain microbleeds, anticoagulation, and hemorrhage risk. Neurology 89:2317\u20132326","journal-title":"Neurology"},{"key":"811_CR117","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fneur.2016.00151","volume":"7","author":"C Karayiannis","year":"2016","unstructured":"Karayiannis C, Soufan C, Chandra RV, Phan TG, Wong K, Singhal S et al (2016) Prevalence of brain MRI markers of hemorrhagic risk in patients with stroke and atrial fibrillation. Front Neurol 7:151","journal-title":"Front Neurol"},{"issue":"6","key":"811_CR118","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1161\/CIRCULATIONAHA.115.016261","volume":"132","author":"S Akoudad","year":"2015","unstructured":"Akoudad S, Portegies MLP, Koudstaal PJ, Hofman A, Lugt Avd, Ikram MA et al (2015) Cerebral microbleeds are associated with an increased risk of stroke. Circulation. 132(6):509\u201316","journal-title":"Circulation."},{"issue":"7","key":"811_CR119","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(19)30197-8","volume":"18","author":"D Wilson","year":"2019","unstructured":"Wilson D, Ambler G, Lee KJ, Lim JS, Shiozawa M, Koga M et al (2019) Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurol 18(7):653\u2013665","journal-title":"Lancet Neurol"},{"issue":"9","key":"811_CR120","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.injury.2015.06.013","volume":"46","author":"MM Boltz","year":"2015","unstructured":"Boltz MM, Podany AB, Hollenbeak CS, Armen SB (2015) Injuries and outcomes associated with traumatic falls in the elderly population on oral anticoagulant therapy. Injury 46(9):1765\u20131771","journal-title":"Injury"},{"issue":"12","key":"811_CR121","first-page":"4380","volume":"26","author":"YL Liu","year":"2022","unstructured":"Liu YL, Yin L, Gu HM, Zhu XJ, Huang XX (2022) Outcomes of elderly patients with traumatic brain injury associated with the pre-injury antithrombotic prophylaxis type\u2014a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 26(12):4380\u20134391","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"811_CR122","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archinte.159.7.677","volume":"159","author":"M Man-Son-Hing","year":"1999","unstructured":"Man-Son-Hing M, Nichol G, Lau A, Laupacis A (1999) Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 159(7):677\u2013685","journal-title":"Arch Intern Med"},{"issue":"8","key":"811_CR123","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40266-021-00870-6","volume":"38","author":"W Wei","year":"2021","unstructured":"Wei W, Rasu RS, Hern\u00e1ndez-Mu\u00f1oz JJ, Flores RJ, Rianon NJ, Hern\u00e1ndez-Vizcarrondo GA et al (2021) Impact of fall risk and direct oral anticoagulant treatment on quality-adjusted life-years in older adults with atrial fibrillation: a Markov decision analysis. Drugs Aging 38(8):713\u2013723","journal-title":"Drugs Aging"},{"issue":"4","key":"811_CR124","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1001\/jamainternmed.2016.9369","volume":"177","author":"PB Nielsen","year":"2017","unstructured":"Nielsen PB, Larsen TB, Skj\u00f8th F, Lip GYH (2017) Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation. JAMA Inten Med 177(4):563\u2013570","journal-title":"JAMA Inten Med"},{"issue":"1","key":"811_CR125","doi-asserted-by":"publisher","first-page":"e0191137","DOI":"10.1371\/journal.pone.0191137","volume":"13","author":"Y Xu","year":"2018","unstructured":"Xu Y, Shoamanesh A, Schulman S, Dowlatshahi D, Salman RA-S, Moldovan ID et al (2018) Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts. PLoS One 13(1):e0191137","journal-title":"PLoS One"},{"issue":"6","key":"811_CR126","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/STROKEAHA.116.016327","volume":"48","author":"SB Murthy","year":"2017","unstructured":"Murthy SB, Gupta A, Merkler AE, Navi BB, Mandava P, Iadecola C et al (2017) Restarting anticoagulant therapy after intracranial hemorrhage. Stroke 48(6):1594\u20131600","journal-title":"Stroke"},{"issue":"7","key":"811_CR127","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1111\/j.1538-7836.2010.03882.x","volume":"8","author":"GWJ Hawryluk","year":"2010","unstructured":"Hawryluk GWJ, Austin JW, Furlan JC, Lee JB, O\u2019Kelly C, Fehlings MG (2010) Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk. J Thromb Haemost 8(7):1500\u20131508","journal-title":"J Thromb Haemost"},{"issue":"13","key":"811_CR128","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1089\/neu.2020.7535","volume":"38","author":"TJ Milling","year":"2021","unstructured":"Milling TJ, Warach S, Johnston SC, Gajewski B, Costantini T, Price M et al (2021) Restart TICrH: an adaptive randomized trial of time intervals to restart direct oral anticoagulants after traumatic intracranial hemorrhage. J Neurotrauma 38(13):1791\u20131798","journal-title":"J Neurotrauma"},{"key":"811_CR129","unstructured":"Joint Formulary Committee (2022) British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Available from: http:\/\/www.medicinescomplete.com. Accessed 2 Oct 2022"},{"issue":"16","key":"811_CR130","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al (2018) The 2018 European Heart Rhythm Association Practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330\u20131393","journal-title":"Eur Heart J"},{"issue":"14","key":"811_CR131","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"J-P Collet","year":"2021","unstructured":"Collet J-P, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL et al (2021) 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 42(14):1289\u20131367","journal-title":"Eur Heart J"},{"issue":"4","key":"811_CR132","doi-asserted-by":"publisher","first-page":"371.e1","DOI":"10.1016\/j.jamda.2017.12.013","volume":"19","author":"M de Vries","year":"2018","unstructured":"de Vries M, Seppala LJ, Daams JG, van de Glind EMM, Masud T, van der Velde N et al (2018) Fall-risk-increasing drugs: a systematic review and meta-analysis: I. Cardiovascular drugs. J Am Med Dir Assoc 19(4):371.e1-e8","journal-title":"J Am Med Dir Assoc"},{"issue":"10","key":"811_CR133","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1111\/jgs.16062","volume":"67","author":"F Dalgaard","year":"2019","unstructured":"Dalgaard F, Pallisgaard JL, Num\u00e9 A-K, Lindhardt TB, Gislason GH, Torp-Pedersen C et al (2019) Rate or rhythm control in older atrial fibrillation patients: risk of fall-related injuries and syncope. J Am Geriatr Soc 67(10):2023\u20132030","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"811_CR134","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/0272989X211005655","volume":"41","author":"VD Torres Roldan","year":"2021","unstructured":"Torres Roldan VD, Brand-McCarthy SR, Ponce OJ, Belluzzo T, Urtecho M, Espinoza Suarez NR et al (2021) Shared decision making tools for people facing stroke prevention strategies in atrial fibrillation: a systematic review and environmental scan. Med Decis Making 41(5):540\u2013549","journal-title":"Med Decis Making"},{"key":"811_CR135","doi-asserted-by":"publisher","unstructured":"Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L (2023) Clinical outcomes in patients with atrial fibrillation and a history of falls using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. IJC Heart Vasc. https:\/\/doi.org\/10.1016\/j.ijcha.2023.101223","DOI":"10.1016\/j.ijcha.2023.101223"},{"issue":"5","key":"811_CR136","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jamda.2014.12.008","volume":"16","author":"S Granziera","year":"2015","unstructured":"Granziera S, Cohen AT, Nante G, Manzato E, Sergi G (2015) Thromboembolic prevention in frail elderly patients with atrial fibrillation: a practical algorithm. J Am Med Dir Assoc 16(5):358\u2013364","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"811_CR137","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12904-021-00786-3","volume":"20","author":"BAA Huisman","year":"2021","unstructured":"Huisman BAA, Geijteman ECT, Arevalo JJ, Dees MK, van Zuylen L, Szadek KM et al (2021) Use of antithrombotics at the end of life: an in-depth chart review study. BMC Palliat Care 20(1):110","journal-title":"BMC Palliat Care"}],"container-title":["European Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-023-00811-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41999-023-00811-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-023-00811-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T16:03:11Z","timestamp":1692806591000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41999-023-00811-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":137,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1007\/s41999-023-00811-z","relation":{},"ISSN":["1878-7657"],"issn-type":[{"value":"1878-7657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]},"assertion":[{"value":"23 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. No funding was received for conducting this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent is not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}